Windtree Therapeutics Inc
NASDAQ:WINT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Windtree Therapeutics Inc
NASDAQ:WINT
|
US |
|
E
|
Efecte Oyj
OMXH:EFECTE
|
FI |
|
Imagion Biosystems Ltd
ASX:IBX
|
AU |
|
PVR INOX Ltd
NSE:PVRINOX
|
IN |
|
Eestech Inc
OTC:EESH
|
US |
|
MyState Ltd
ASX:MYS
|
AU |
|
Hexagon AB
OTC:HXGBF
|
SE |
|
Novogene Co Ltd
SSE:688315
|
CN |
|
Zhejiang Chint Electrics Co Ltd
SSE:601877
|
CN |
|
China Zhonghua Geotechnical Engineering Group Co Ltd
SZSE:002542
|
CN |
|
X
|
Xinjiang International Industry Co Ltd
SZSE:000159
|
CN |
|
Electricite de France SA
PAR:EDF
|
FR |
|
Yes Bank Ltd
NSE:YESBANK
|
IN |
|
CSR Ltd
ASX:CSR
|
AU |
|
B
|
BEH-Property Co Ltd
SSE:600791
|
CN |
|
IMAX China Holding Inc
HKEX:1970
|
CN |
|
DoubleDown Interactive Co Ltd
NASDAQ:DDI
|
KR |
|
Kerry Logistics Network Ltd
HKEX:636
|
HK |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
CN |
|
A
|
Allied Copper Corp
XTSX:CPR
|
CA |
|
Huapont Life Sciences Co Ltd
SZSE:002004
|
CN |
Windtree Therapeutics Inc
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company, which engages in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 33 full-time employees. The Company’s development programs are primarily focused on the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. Its Cardiovascular Program’s products candidates include Istaroxime, Oral SERCA2a Activators and Rostafuroxin. Its Pulmonary Program’s product candidates include Lyophilized KL4 Surfactant and AEROSURF (aerosolized KL4 surfactant based on ADS technology). The Company’s lead product candidate, istaroxime, is a dual-acting agent being developed to improve cardiac function in patients with acute heart failure (AHF) with a potentially differentiated safety profile from existing treatments. Istaroxime demonstrated significant improvement in both diastolic and systolic aspects of cardiac function and is under phase II clinical trials.
